title: VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444).
abstract: BACKGROUND
  Epidemiological studies suggest that raised plasma concentrations of total homocysteine (tHcy) may be a common, causal and treatable risk factor for atherothromboembolic ischaemic stroke, dementia and depression. Although tHcy can be lowered effectively with small doses of folic acid, vitamin B(12) and vitamin B(6), it is not known whether lowering tHcy, by means of B vitamin therapy, can prevent stroke and other major atherothromboembolic vascular events.
  
  
  OBJECTIVE
  To determine whether the addition of B-vitamin supplements (folic acid 2 mg, B(6) 25 mg, B(12) 500 microg) to best medical and surgical management will reduce the combined incidence of stroke, myocardial infarction (MI) and vascular death in patients with recent stroke or transient ischaemic attack (TIA) of the brain or eye.
  
  
  METHODS
  A prospective, international, multicentre, randomised, double blind, placebo-controlled clinical trial.
  
  
  METHODS
  One hundred and four medical centres in 20 countries on five continents.
  
  
  METHODS
  Eight thousand (6600 recruited as of 5 January, 2006) patients with recent (<7 months) stroke (ischaemic or haemorrhagic) or TIA (brain or eye).
  
  
  METHODS
  Randomisation and data collection are performed by means of a central telephone service or secure internet site.
  
  
  METHODS
  One tablet daily of either placebo or B vitamins (folic acid 2 mg, B(6) 25 mg, B(12) 500 mug).
  
  
  METHODS
  The composite of stroke, MI or death from any vascular cause, whichever occurs first. Outcome and serious adverse events are adjudicated blinded to treatment allocation.
  
  
  RESULTS
  TIA, unstable angina, revascularisation procedures, dementia, depression. STATISTICAL POWER: With 8000 patients followed up for a median of 2 years and an annual incidence of the primary outcome of 8% among patients assigned placebo, the study will have at least 80% power to detect a relative reduction of 15% in the incidence of the primary outcome among patients assigned B vitamins (to 6.8%/year), applying a two-tailed level of significance of 5%.
  
  
  CONCLUSIONS
  VITATOPS aims to recruit and follow-up 8000 patients between 1998 and 2008, and provide a reliable estimate of the safety and effectiveness of folic acid, vitamin B(12), and vitamin B(6) supplementation in reducing recurrent serious vascular events among a wide range of patients with TIA and stroke throughout the world.
authors.forename: G J
authors.initials: GJ
authors.lastname: Hankey
authors.forename: A
authors.initials: A
authors.lastname: Algra
authors.forename: C
authors.initials: C
authors.lastname: Chen
authors.forename: M C
authors.initials: MC
authors.lastname: Wong
authors.forename: R
authors.initials: R
authors.lastname: Cheung
authors.forename: L
authors.initials: L
authors.lastname: Wong
authors.forename: I
authors.initials: I
authors.lastname: Divjak
authors.forename: J
authors.initials: J
authors.lastname: Ferro
authors.forename: G
authors.initials: G
authors.lastname: de Freitas
authors.forename: J
authors.initials: J
authors.lastname: Gommans
authors.forename: S
authors.initials: S
authors.lastname: Groppa
authors.forename: M
authors.initials: M
authors.lastname: Hill
authors.forename: D
authors.initials: D
authors.lastname: Spence
authors.forename: K
authors.initials: K
authors.lastname: Lees
authors.forename: L
authors.initials: L
authors.lastname: Lisheng
authors.forename: J
authors.initials: J
authors.lastname: Navarro
authors.forename: U
authors.initials: U
authors.lastname: Ranawaka
authors.forename: S
authors.initials: S
authors.lastname: Ricci
authors.forename: R
authors.initials: R
authors.lastname: Schmidt
authors.forename: A
authors.initials: A
authors.lastname: Slivka
authors.forename: K
authors.initials: K
authors.lastname: Tan
authors.forename: A
authors.initials: A
authors.lastname: Tsiskaridze
authors.forename: W
authors.initials: W
authors.lastname: Uddin
authors.forename: G
authors.initials: G
authors.lastname: Vanhooren
authors.forename: D
authors.initials: D
authors.lastname: Xavier
authors.forename: J
authors.initials: J
authors.lastname: Armitage
authors.forename: M
authors.initials: M
authors.lastname: Hobbs
authors.forename: M
authors.initials: M
authors.lastname: Le
authors.forename: C
authors.initials: C
authors.lastname: Sudlow
authors.forename: K
authors.initials: K
authors.lastname: Wheatley
authors.forename: Q
authors.initials: Q
authors.lastname: Yi
authors.forename: M
authors.initials: M
authors.lastname: Bulder
authors.forename: J W
authors.initials: JW
authors.lastname: Eikelboom
authors.forename: G J
authors.initials: GJ
authors.lastname: Hankey
authors.forename: W K
authors.initials: WK
authors.lastname: Ho
authors.forename: K
authors.initials: K
authors.lastname: Jamrozik
authors.forename: K
authors.initials: K
authors.lastname: Klijn
authors.forename: E
authors.initials: E
authors.lastname: Koedam
authors.forename: P
authors.initials: P
authors.lastname: Langton
authors.forename: E
authors.initials: E
authors.lastname: Nijboer
authors.forename: P
authors.initials: P
authors.lastname: Tuch
authors.forename: J
authors.initials: J
authors.lastname: Pizzi
authors.forename: M
authors.initials: M
authors.lastname: Tang
authors.forename: M
authors.initials: M
authors.lastname: Antenucci
authors.forename: Y
authors.initials: Y
authors.lastname: Chew
authors.forename: D
authors.initials: D
authors.lastname: Chinnery
authors.forename: C
authors.initials: C
authors.lastname: Cockayne
authors.forename: K
authors.initials: K
authors.lastname: Loh
authors.forename: L
authors.initials: L
authors.lastname: McMullin
authors.forename: F
authors.initials: F
authors.lastname: Smith
authors.forename: R
authors.initials: R
authors.lastname: Schmidt
authors.forename: C
authors.initials: C
authors.lastname: Chen
authors.forename: M C
authors.initials: MC
authors.lastname: Wong
authors.forename: G
authors.initials: G
authors.lastname: de Freitas
authors.forename: G J
authors.initials: GJ
authors.lastname: Hankey
authors.forename: K
authors.initials: K
authors.lastname: Loh
authors.forename: S
authors.initials: S
authors.lastname: Song
mesh_terms: D006801:Humans; D002546:Ischemic Attack, Transient / Q000517:prevention & control*; D012107:Research Design; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control*; D014803:Vitamin B Complex / Q000627:therapeutic use*
chemical_list: D014803:Vitamin B Complex